SARS-CoV-2 Mpro-IN-9
SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM) [1].
Product Specifications
CAS Number
2754370-99-3
UNSPSC
12352005
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-mpro-in-9.html
Solubility
10 mM in DMSO
Smiles
O=C1N(C2=CC=CC=C2)C(C3=CC=CC=C3)=NC4=C1C(O)=C(O)C(O)=C4
Molecular Formula
C20H14N2O4
Molecular Weight
346.34
References & Citations
[1]Zhang K, et al. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro) . Eur J Med Chem. 2023 Sep 5;257:115487.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
